Medifast, Inc. (MED)

Medifast, Inc. topped estimates on both revenue and EPS in the second fiscal quarter of 2026, reported on August 3, as revenue fell about 28% year over year to about $76.4 million, still above the roughly $72.7 million estimate by about 5%, while EPS of -$0.28 beat the -$0.65 consensus by about 57%. Net income swung to a loss of about $3.1 million, down 225% year over year from $2.5 million a year ago, with gross margin near 70% and operating margin around -6% as operating loss came to about $4.3 million. Operating cash flow was about $1.7 million, and the company paid $83,000 in dividends. Next-period consensus calls for EPS of -$0.60 on revenue of $71.3 million.